The stock of Edgewise Therapeutics Inc (NASDAQ: EWTX) has decreased by -9.84 when compared to last closing price of 14.33.Despite this, the company has seen a loss of -10.71% in its stock price over the last five trading days. prnewswire.com reported 2025-06-26 that – New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker – – Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 – – Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The 36-month beta value for EWTX is at 0.29. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for EWTX is 77.10M, and currently, shorts hold a 16.25% of that float. The average trading volume for EWTX on June 26, 2025 was 1.59M shares.
EWTX’s Market Performance
EWTX’s stock has seen a -10.71% decrease for the week, with a -9.81% drop in the past month and a -41.96% fall in the past quarter. The volatility ratio for the week is 4.36%, and the volatility levels for the past 30 days are at 4.83% for Edgewise Therapeutics Inc The simple moving average for the past 20 days is -12.17% for EWTX’s stock, with a -46.57% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Guggenheim repeating the rating for EWTX by listing it as a “Buy.” The predicted price for EWTX in the upcoming period, according to Guggenheim is $41 based on the research report published on April 30, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $14. The rating they have provided for EWTX stocks is “Sector Perform” according to the report published on April 02nd, 2025.
Scotiabank gave a rating of “Sector Outperform” to EWTX, setting the target price at $50 in the report published on March 07th of the current year.
EWTX Trading at -12.20% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 1,551 shares at the price of $16.45 back on May 02 ’25. After this action, Russell Alan J now owns 18,521 shares of Edgewise Therapeutics Inc, valued at $25,520 using the latest closing price.
MOORE JOHN R, the General Counsel of Edgewise Therapeutics Inc, sale 1,930 shares at $16.45 during a trade that took place back on May 02 ’25, which means that MOORE JOHN R is holding 6,531 shares at $31,757 based on the most recent closing price.
Stock Fundamentals for EWTX
The total capital return value is set at -0.39. Equity return is now at value -30.29, with -28.98 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -25.95.
Currently, EBITDA for the company is -131.52 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.99.
Conclusion
In conclusion, Edgewise Therapeutics Inc (EWTX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
